![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
RUBY-II: Efficacy and Safety of a Ribavirin-Free Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir Regimen in Patients
With Severe Renal Impairment or End-Stage Renal Disease and HCV Genotype 1a or 4 Infection
|
|
|
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Edward Gane1, Ricard Sola2, Eric Cohen3, Stuart K Roberts4, Jacob George5, Richard Skoien6, Stephen Riordan7, Niloufar Mobashery3, Manal Abunimeh3, Daniel E Cohen3, Kosh Agarwal8
1Auckland City Hospital, Auckland, New Zealand; 2Hospital del Mar. IMIM, Universitat Autónoma de Barcelona, Barcelona, Spain; 3AbbVie Inc., North Chicago, Illinois, United States; 4Alfred Hospital, Melbourne, Australia; 5Westmead Hospital, Westmead Insti tute for Medical Research and University of Sydney, Westmead, Australia; 6Royal Brisbane and Women's Hospital, Brisbane, Australia; 7University of New South Wales, Randwick, Australia; 8Insti tute of Liver Studies, Kings College Hospital NHS Foundation Trust, London, United Kingdom
![HIV1](../images/111616/111616-3/HIV1.gif)
![HIV2](../images/111616/111616-3/HIV2.gif)
![HIV3](../images/111616/111616-3/HIV3.gif)
![HIV4](../images/111616/111616-3/HIV4.gif)
![HIV5](../images/111616/111616-3/HIV5.gif)
![HIV6](../images/111616/111616-3/HIV6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|